Study of RAP-219 for Focal Seizures
This study is testing an investigational drug called RAP-219 to see if it can safely and effectively reduce the number of focal seizures (seizures that start in one area of the brain) in adults. You may be able to join if you are between 18 and 75 years old, have been diagnosed with focal epilepsy for at least two years, and are currently taking 1 to 3 other anti-seizure medications. The study will measure how much your seizure frequency changes after about 14 weeks of treatment. This study is currently recruiting participants.
- Study design
- This is an interventional study where about 312 participants will be randomly assigned to receive either a medium dose of RAP-219, a low dose of RAP-219, or a placebo (an inactive pill).
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- After the main treatment period, participants will either join a long-term safety study or have an 8-week follow-up period.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures
At a glance
Conditions
Where it's being run
6 sites across 5 statesStudy leadership
- Vicente Villaneuva, M.D., PhD · PRINCIPAL_INVESTIGATOR · Hospital Universitari i Politecnic La Fe, Spain
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Median Percent Change in Seizure FrequencyEnd of double-blind treatment period (end of week 14) vs Baseline
Median percent change in seizure frequency and ≥ 50% seizure frequency reduction responder rates